U.N. Office on Drugs, Interpol better equipped than WHO to combat counterfeit drug trade

NewsGuard 100/100 Score

"The worldwide counterfeit drug market is huge and growing," Tim Mackey and Brian Liang of the Institute of Health Law Studies at the California Western School of Law and Thomas Kubic of the Pharmaceutical Security Institute write in a Foreign Policy opinion piece, noting such "drugs occupy a wide spectrum of medications, and their quality is suspect; they can be mislabeled, tainted, adulterated, ineffective, or, in the worst cases, all of the above." They argue for a new framework for fighting the illegal drug trade because "[g]lobal policy has not kept up with the burgeoning counterfeit drug trade." The authors say that although initial results of the WHO IMPACT (International Medical Products Anti-Counterfeit Taskforce) are "encouraging," they note that "[s]ome WHO member states, including India and Brazil (both top producers of generic drugs) and other developing countries, have questioned whether WHO can rightly take on enforcement operations" because it "is not a global law enforcement agency."

Instead, they argue that "[a] better institutional bearer for the fight against counterfeit drugs could be the U.N. Office on Drugs and Crime (UNODC)," which would "ideally be supported by the International Criminal Police Organization (Interpol)." In such a case, they write, "WHO would be freed up to operate as the technical and research agency that it is, assessing and recommending measures to deal with public health issues arising from counterfeit medicines." The authors conclude, "The counterfeit drug trade is a tremendous global health problem, threatening millions of lives worldwide. If agencies do not come together to end it, criminals will continue to meet growing demand and reap profits as everyone else suffers. If they do come together, the battle against perhaps the most menacing public health and patient safety threat of this generation can be won, and all of us can be assured that the medicines we use are safe" (5/14).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New hope for binge eating and bulimia: GLP-1 drugs could be the key